Form 4: Turn Therapeutics Board Observer Buys Shares
Insider Transaction Report
Abraham Chesed, a Board Observer for Turn Therapeutics Inc., acquired 14,286 shares of common stock at $4.60 per share.
Summary
- Abraham Chesed, a Board Observer for Turn Therapeutics Inc. (TTRX), purchased 14,286 shares of common stock.
- The transaction occurred on October 23, 2025, at a price of $4.60 per share.
- The shares were acquired indirectly through ANC Merchant FLP and ANC Carlson FLP.
- Following this transaction, Abraham Chesed indirectly beneficially owns a total of 1,447,268 shares.
- The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 7
Explanation: The insider purchase by a Board Observer indicates a positive sentiment and confidence in the company's future, especially when conducted under a 10b5-1 plan.
Positives
- The purchase by a Board Observer signals confidence in the company's future prospects.
- The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned acquisition rather than a reactive one.
Industry Context
Insider purchases, especially by individuals with close ties to company operations like a Board Observer, are often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that significant positive developments are anticipated.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transaction was made pursuant to a Rule 10b5-1(c) plan, which allows insiders to set up a pre-arranged plan to buy or sell company stock to avoid accusations of insider trading. | 10/23/2025 | Enhances transparency and provides a legal defense against insider trading allegations, demonstrating adherence to regulatory best practices. |
Related Party Transactions
- The shares are held indirectly through ANC Merchant FLP and ANC Carlson FLP, where the reporting person owns 48%, the reporting person's spouse owns 48%, and each of the reporting person's two children owns 2%.
Stakeholder Impact
- Shareholders may view this insider purchase as a positive indicator of management's confidence in the company's valuation and future performance.
Key Dates
| Date | Description |
|---|---|
| 10/23/2025 | Date of earliest transaction (acquisition of common stock) |
| 10/29/2025 | Signature date of the reporting person |
Recommendation
buyThe purchase of shares by a Board Observer, particularly under a Rule 10b5-1 plan, typically signals strong insider confidence in the company's prospects and potential for stock appreciation. This action suggests that an individual with privileged insight into Turn Therapeutics believes the stock is a good investment at the current price, making it a positive signal for potential investors.
Keywords
Turn Therapeutics, TTRX, Insider Trading, Form 4, Stock Purchase, Abraham Chesed, Board Observer, Equity Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.